Facilitators and barriers in the donor family interview process from the perspective of hospital staff: a cross-sectional study.

Background: Obtaining consent from potential donor families is a challenging step in the donation process and is influenced by various factors. Methods: In this cross-sectional study, we utilized a questionnaire containing 14 questions about facilitators and barriers in the family interview process. The questionnaire was distributed in March 2023 to intensive care unit (ICU) nurses who had experience with donor family interviews. We collected the opinions of these respondents on hospital performance and drew comparisons between the studied hospitals. Results: A total of 60 participating ICU nurses provided mean scores for hospital performance in family interviews of 2.60±0.84 for type I hospitals (those providing neurosurgery and trauma care) and 2.035±0.890 for type II hospitals (those without neurosurgery and trauma services; P=0.04). The mean scores for public and private hospitals were 1.86±0.86 and 2.59±0.85, respectively (P=0.008). Based on the findings, the most important facilitators were the availability of organ donation staff and access to a professional team for family discussions. Conversely, poor physician communication skills and limited communication capabilities among medical staff were identified as significant barriers. Implementation of a professional team for family interviews was found to be more critical for type II hospitals. Poor physician communication skills were a significant concern in public hospitals, while families' lack of awareness of patient prognosis emerged as a key barrier in private hospitals. Conclusions: This study highlights numerous facilitators and barriers that vary across hospitals. Addressing these issues individually and developing tailored plans to enhance hospital performance in interviewing donor families is essential.

Organ Procurement From Donors After Brain Death During the COVID-19 Pandemic: Experience of a High Prevalence Country.

OBJECTIVES: Our aim was to compare the donation process before and after the COVID-19 pandemic in an organ procurement unit in Iran and to discuss different strategies to address the impact of the pandemic on the donation process. MATERIALS AND METHODS: All activities including donor detection, donor selection, family approach, donors characteristics, rate of organs per donor, and types of organs were compared between 2 intervals over 18 months (March 2020 to June 2021 [during the COVID19 pandemic] vs November 2018 to February 2020 [before the pandemic]). RESULTS: Before and during the COVID-19 pandemic, there were 218 and 137 brain dead donors with mean age of 42.6 ± 14.5 and 42.8 ± 15.5 years, respectively (P = .82). The prevalence of tumors leading to brain death decreased by more than half during the COVID-19 pandemic (P = .04). There was a 52% increase in cardiac death before organ retrieval during the COVID-19 pandemic, reaching 38% from 25% before COVID-19. During the 2 intervals, the number of organs per donor was 2.3 ± 1.2 and 2.2 ± 1.2 (P = .52). The rate of actual to potential donors before and during the pandemic was significantly different, with 42.16 ± 7.8% before and 29.9 ± 4.8% during the pandemic, mostly as a result of unsuitable donors. The time to obtain family consent during the COVID-19 pandemic was 35.1 ± 8.5 hours, which was a significantly longer length of time than before the pandemic (21.3 ± 12.3 hours; P = .008). CONCLUSIONS: In our organ procurement unit, which encompasses a population of 5.5 million in Tehran, Iran, the number of actual donors was reduced dramatically during the studied pandemic period. However, despite a high workload, all transplant centers and organ procurement units in Iran worked to identify and transplant the available organs to reduce wait list mortality.

Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.

Background: Remdesivir is effective against SARS-Cov-2 with little evidence of its adverse effect on the cardiac system. The aim of the present study is investigating the incidence of bradycardia in COVID-19 patients treated with Remdesivir. Methods: This prospective longitudinal study was conducted in a tertiary center on COVID-19 patients for Remdesivir therapy. The objectives were to investigate the incidence of sinus bradycardia, and also the association between their demographics, underlying diseases, and the disease severity with developing bradycardia in COVID-19 patients treated with Remdesivir. Results: Of 177 patients, 44% were male. The mean (±standard deviation) age of patients was 49.79 ± 15.16 years old. Also, 33% were hospitalized due to more severe symptoms. Oxygen support was required for all hospitalized subjects. A total of 40% of the patients had comorbidities, with the most common comorbidity being hypertension. The overall incidence of bradycardia (heart rate<60 bpm) in patients receiving Remdesivir was 27%, of whom 70% had extreme bradycardia (heart rate <50 bpm). There was also a statistically significant reduction in heart rate after five doses of Remdesivir compared to the baseline heart rates. In the multivariable model, none of the covariates including age above 60 years, female sex, CRP>50 mg/L, O2 saturation<90%, underlying cardiovascular disease, hypertension and diabetes mellitus, and beta-blockers were associated with Remdesivir-induced bradycardia. No association was found between the COVID-19 severity indicators and bradycardia. Conclusion: As sinus bradycardia is a prevalent adverse cardiac effect of Remdesivir, it is recommended that all COVID-19 patients receiving Remdesivir, be evaluated for heart rate based on examination; and in the case of bradyarrhythmia, cardiac monitoring should be performed during administration to prevent adverse drug reactions.